Supportive information Table 5: Univariable and multivariable linear regression analyses to evaluate the influence of various variables on macrovesicular steatosis. Bold p-values (<0.150) in univariable regression analysis were included in multivariable regression analysis.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variables** | | **Univariable** | | | **Multivariable** |
| **R2** | | **p-value** | **p-value** |
| *Pre-operative details* | |  |  |  |  |
| Male gender | | <0.001 | | 0.814 |  |
| Age at resection of metastases in years | | 0.009 | | **0.092** |  |
| *Body mass index* | | *0.203* | | ***<0.001*** | ***<0.001*** |
| *Hemoglobin in g/dl* | | *0.043* | | ***<0.001*** |  |
| Leukocytes in tsd/µl | | <0.001 | | 0.949 |  |
| Platelets in tsd/µl | | 0.004 | | 0.277 |  |
| *Quick in %* | | *0.028* | | ***0.003*** | ***0.005*** |
| ASAT (GOT) in U/l | | <0.001 | | 0.994 |  |
| Creatinine in µmol/l | | 0.001 | | 0.505 |  |
| Resection severity index | | <0.001 | | 0.700 |  |
| Fibrosis-4 score | | 0.013 | | **0.077** |  |
|  |  |  |  |  |  |
| *Therapy of metastases* | |  |  |  |  |
| Neoadjuvant chemotherapy 5-FU + Oxaliplatin | | 0.001 | | 0.613 |  |
| Neoadjuvant chemotherapy 5-FU + Irinotecan | | 0.009 | | **0.095** |  |
| Neoadjuvant chemotherapy Other | | 0.005 | | 0.189 |  |
|  |  |  |  |  |  |
| *Primary tumor characteristics* | |  |  |  |  |
| Location | Cecum | 0.017 | | 0.365 |  |
| Colon ascendens |
| Colon transversum |
| *Colon descendens* |
| Colon sigmoideum |
| Rectum |
| UICC 7 stages | I | 0.023 | | 0.353 |  |
| IIa |
| IIb |
| IIIa |
| IIIb |
| IIIc |
| IV |
| Tumor grading | G1 | 0.004 | | 0.596 |  |
| G2 |
| G3 |
| R status | R0 | 0.003 | | 0.345 |  |
| R1 |
| *Neoadjuvant chemotherapy 5-FU* | | *0.001* | | *0.672* |  |
| *Neoadjuvant chemotherapy 5-FU + Oxaliplatin* | | *0.003* | | *0.352* |  |
| *Neoadjuvant chemotherapy Other* | | *0.001* | | *0.524* |  |
| *Adjuvant chemotherapy 5-FU* | | *0.001* | | *0.620* |  |
| *Adjuvant chemotherapy 5-FU + Oxaliplatin* | | *0.008* | | ***0.105*** |  |
| *Adjuvant chemotherapy 5-FU + Irinotecan* | | *0.006* | | *0.156* |  |
| *Adjuvant chemotherapy Other* | | *0.002* | | *0.441* |  |
| *Conversion chemotherapy 5-FU* | | *0.012* | | ***0.049*** |  |
| *Conversion chemotherapy 5-FU + Oxaliplatin* | | *0.018* | | ***0.016*** | ***0.003*** |
| *Conversion chemotherapy 5-FU + Irinotecan* | | *0.008* | | ***0.111*** |  |
| Adjuvant radiation | | <0.001 | | 0.861 |  |
| *Local relapse* | | *0.018* | | ***0.016*** | ***0.003*** |
|  |  |  |  |  |  |
| *Operative details* | |  |  |  |  |
| Left atypical liver resection | | 1 point | 0.021 | 0.355 |  |
| Right atypical liver resection | |
| Left segmental liver resection | | 2 points |
| Right segmental liver resection | |
| Bilateral atypical liver resection | |
| Left hemihepatectomy | | 3 points |
| Right hemihepatectomy | | 4 points |
| Extended left hepatectomy | | 5 points |
| Extended right hepatectomy | | 6 points |
| Left hepatectomy and right atypical liver resection | |
| Right hepatectomy and left atypical resection | | 7 points |
| Operative duration in min | | <0.001 | | 0.899 |  |
| Duration of Pringle’s maneuver in min | | 0.002 | | 0.383 |  |
| Intra-operative transfusion of pRBCs | | 0.024 | | **0.005** |  |
| Units of intra-operatively transfused pRBCs | | 0.013 | | **0.042** |  |
| Grading | G1 | 0.002 | | 0.761 |  |
| metastases | G2 |
|  | G3 |
| R status | R0 | 0.002 | | 0.738 |  |
| R1 |
| R2 |
| Distance to resection margin in mm | | <0.001 | | 0.969 |  |
| Size of largest metastases in mm | | 0.031 | | **0.002** | **0.006** |